Proactive Investors - Run By Investors For Investors

Immunoprecise Antibodies reports 2Q revenue doubled on increased capacity, European expansion

Highlights for the company included the purchases of U-Protein Express and ModiQuest Research
An illustration of antibodies
The antibodies developer cited an 'impressive increase' in the scale of services requested by prospects and clients

Immunoprecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) said its quarterly revenue doubled as the company increased capacity and expanded market share in Europe.

The Victoria, British Columbia-based biotech said late Monday in a press release that it increased high-margin projects at its B-cell lab and expanded in Europe by acquiring U-Protein Express and ModiQuest Research.

READ: Immunoprecise Antibodies adds new platforms to its range of services

For the second quarter ended October 31, the company reported that revenue climbed to C$2.7 million from C$1.3 million a year earlier. The net loss widened to C$1.5 million from C$903,000 as a result of additional staffing for projects.

“There has been an impressive increase in the scale of services requested by prospects and clients, further confirming the value of investing in our global presence,” Dr Jennifer Bath, CEO and president of Immunoprecise, said in a statement. "We are happy with our second-quarter performance.”

Immunoprecise reported that its gross margin increased to 52% from 41% and expects it to stay above 50% for the rest of fiscal 2019. As of October 31, the company said it had cash on hand of C$8.8 million and working capital of almost C$8.2 million.

Shares of the company fetched C$0.71 in Monday’s Canadian trading. They slipped US$0.01 to US$0.51 on the OTC Markets.

In late December, the company announced that Jason Orloske had accepted the position of vice president of operations for the company's global division.

Contact Dennis Fitzgerald at [email protected]


View full IPA profile View Profile

ImmunoPrecise Antibodies Ltd Timeline

Related Articles

Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use